<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617664</url>
  </required_header>
  <id_info>
    <org_study_id>treatment of primary nocturnal</org_study_id>
    <nct_id>NCT05617664</nct_id>
  </id_info>
  <brief_title>Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis</brief_title>
  <official_title>Is Mirabegron 25 mg Safe and Effective in Treatment of Primary Nocturnal Enuresis as Regard Oral Desmopressin 120 mcg?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will study the efficacy and safety of mirabegron25 in treatment of primary&#xD;
      nocturnal enuresis in comparison to oral desmopressin 120 mcg and behavioral therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No doubt that nocturnal enuresis is one of the commonest types of urinary incontinence which&#xD;
      affect children and always run in family . Nocturnal enuresis occurs at the age of 5 years&#xD;
      with leakage of urine involuntarily during sleep for two times or more per week in three&#xD;
      consecutive months not due to congenital or acquired cause. Nocturnal enuresis can be&#xD;
      categorized into primary or secondary depending on occurrence of bed dryness for more than&#xD;
      six months or not .&#xD;
&#xD;
      Nocturnal enuresis affects 15% to 20 % of children at five years old mainly due to delay of&#xD;
      bladder development and function more in male children with presence of family history in&#xD;
      half of cases but 15% of children with enuresis recover spontaneously every year .&#xD;
&#xD;
      limitation of fluid intake, urotherapy and bedwetting alarms are non-pharmacological&#xD;
      treatments of nocturnal enuresis while the mostly used drugs for treatment of NE are&#xD;
      tricyclic antidepressants(Imipramine®) an arginine vasopressin analog (Desmopressin®) and&#xD;
      anticholinergic drugs . Enuresis alarms have pitfalls which disgust a lot of patients as skin&#xD;
      irritation, sleep disturbances of other family members and failure to wake the child so that&#xD;
      about 30% of patients stop its usage .&#xD;
&#xD;
      Desmopressin is approved as a first-line drug therapy for nocturnal enuresis , but a lot of&#xD;
      series declared that monotherapy with desmopressin has little efficacy in treating patients&#xD;
      which have bladder storage dysfunction furthermore, high recurrence rate after treatment&#xD;
      cessation .&#xD;
&#xD;
      The International Children's Continence Society (ICCS) recommended combination therapy for&#xD;
      treatment of primary nocturnal enuresis after failure of first line therapy with desmopressin&#xD;
      or enuresis alarms . As regard anticholinergic drugs, oxybutynin was firstly prescribed then&#xD;
      tolterodine with less side effects and lately solifenacin . Cognitive impairment as a&#xD;
      neurological side effect was authenticated for oxybutynin and other side effects (e.g.&#xD;
      headache, dry mouth, behavior change, flushed cheeks, constipation, and blurred vision) were&#xD;
      unbearable to many children and impulsed them to stop treatment early .&#xD;
&#xD;
      Mirabegron, a b3-adrenoceptor (b3-AR) agonist was the answer to the question about a drug&#xD;
      that can relax detrusor muscle and increasing bladder capacity without the limitations of&#xD;
      anti-cholinergic drugs. Mirabegron is the first b3-AR agonist to be prescribed clinically for&#xD;
      OAB symptoms in adults and showed promising outcomes . while it is not licensed to be used in&#xD;
      children with overactive bladder, some early reports declared its efficacy and tolerability&#xD;
      in children .&#xD;
&#xD;
      So investigators will study the efficacy and safety of mirabegron in treatment of primary&#xD;
      nocturnal enuresis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nocturnal enuresis improvement rate</measure>
    <time_frame>four months</time_frame>
    <description>decrease number of nights or absent nights the patient get wet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects of drugs used</measure>
    <time_frame>three months</time_frame>
    <description>appearance of any side effect of desmopressin or mirabegron</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Nocturnal Enuresis</condition>
  <arm_group>
    <arm_group_label>patients with primary nocturnal enuresis will be followed up with behavioral therapy alone.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with primary nocturnal enuresis will take desmopressin 120 mcg oral tablets.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with PNE will take mirabegron 25 mg oral tablets.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desmopressin 120 mcg oral tablets</intervention_name>
    <description>treatment for three months then will stop</description>
    <arm_group_label>patients with primary nocturnal enuresis will take desmopressin 120 mcg oral tablets.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron 25 MG Oral Tablet, Extended Release</intervention_name>
    <description>treatment for three months then will stop</description>
    <arm_group_label>patients with PNE will take mirabegron 25 mg oral tablets.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>behavioral therapy alone</intervention_name>
    <description>no medications will be given to the patient</description>
    <arm_group_label>patients with primary nocturnal enuresis will be followed up with behavioral therapy alone.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  primary nocturnal enuresis,&#xD;
&#xD;
          -  negligible daytime wetting,&#xD;
&#xD;
          -  wet at least 4 times over 4 weeks&#xD;
&#xD;
          -  normal clinical examination with no neurological or urological cause for the enuresis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary enuresis, polysymptomatic&#xD;
&#xD;
          -  neurologic bladder, neurological disorders,&#xD;
&#xD;
          -  urinary incontinence disorders&#xD;
&#xD;
          -  previous anti NE drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>hosam abu el-nasr, MD</last_name>
    <phone>01286296939</phone>
    <phone_ext>002</phone_ext>
    <email>hosamabuelnasr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohamed al hefnawy, MD</last_name>
    <phone>01003481084</phone>
    <phone_ext>002</phone_ext>
    <email>drmohamed@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Benha University Hospitals</name>
      <address>
        <city>Banhā</city>
        <state>Qaliopia</state>
        <zip>13518</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hosam abu el-nasr, MD</last_name>
      <phone>01286296939</phone>
      <phone_ext>002</phone_ext>
      <email>hosamabuelnasr@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Bayne AP, Skoog SJ. Nocturnal enuresis: an approach to assessment and treatment. Pediatr Rev. 2014 Aug;35(8):327-34; quiz 335. doi: 10.1542/pir.35-8-327.</citation>
    <PMID>25086164</PMID>
  </results_reference>
  <results_reference>
    <citation>Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013 Oct;190(4):1320-7. doi: 10.1016/j.juro.2013.05.062. Epub 2013 May 30.</citation>
    <PMID>23727415</PMID>
  </results_reference>
  <results_reference>
    <citation>Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stolzel M, Martin N, Gunther A, Van Kerrebroeck P. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013 Aug;82(2):313-20. doi: 10.1016/j.urology.2013.02.077. Epub 2013 Jun 13. Erratum In: Urology. 2013 Dec;82(6):1457.</citation>
    <PMID>23769122</PMID>
  </results_reference>
  <results_reference>
    <citation>Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Eur Urol. 2016 Jul;70(1):9-13. doi: 10.1016/j.eururo.2016.02.007. Epub 2016 Feb 11.</citation>
    <PMID>26876327</PMID>
  </results_reference>
  <results_reference>
    <citation>Park JS, Lee YS, Lee CN, Kim SH, Kim SW, Han SW. Efficacy and safety of mirabegron, a beta3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2019 Aug;37(8):1665-1670. doi: 10.1007/s00345-018-2576-0. Epub 2018 Dec 3.</citation>
    <PMID>30511212</PMID>
  </results_reference>
  <results_reference>
    <citation>Vande Walle J, Rittig S, Bauer S, Eggert P, Marschall-Kehrel D, Tekgul S; American Academy of Pediatrics; European Society for Paediatric Urology; European Society for Paediatric Nephrology; International Children's Continence Society. Practical consensus guidelines for the management of enuresis. Eur J Pediatr. 2012 Jun;171(6):971-83. doi: 10.1007/s00431-012-1687-7. Epub 2012 Feb 24. Erratum In: Eur J Pediatr. 2012 Jun;171(6):1005. Eur J Pediatr. 2013 Feb;172(2):285.</citation>
    <PMID>22362256</PMID>
  </results_reference>
  <results_reference>
    <citation>Neveus T, Fonseca E, Franco I, Kawauchi A, Kovacevic L, Nieuwhof-Leppink A, Raes A, Tekgul S, Yang SS, Rittig S. Management and treatment of nocturnal enuresis-an updated standardization document from the International Children's Continence Society. J Pediatr Urol. 2020 Feb;16(1):10-19. doi: 10.1016/j.jpurol.2019.12.020. Epub 2020 Jan 30.</citation>
    <PMID>32278657</PMID>
  </results_reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 29, 2022</last_update_submitted>
  <last_update_submitted_qc>November 29, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Hosam Abu El-nasr</investigator_full_name>
    <investigator_title>lecturer of urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Nocturnal Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

